TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02305160
Drug: Butantan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of Butantan surfactant 100 mg/kg, IT, maximum of 3 doses
Study: NCT02193334
Drug: KP-100IT
Normalized name: Draxxin KP
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02193334
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01161134
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meloxicam Tablets 15 mg
Study: NCT00026299
Drug: ZD1839
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01352416
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1000mg (2-500mg tablets) twice daily. Starting 2 days prior to surgery, morning of surgery and up to 14 days post operative depending when the breathing tube is removed from the patient post operative. If intolerant to the study drug due to adverse effects or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily
Study: NCT02052011
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00658047
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg/week for 2 weeks escalated to 15mg/week for 2 weeks escalated to 20mg/week for 8 weeks
Study: NCT04124042
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a sterile phosphate-buffered saline
Study: NCT03520647
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This research protocol is therefore designed to evaluate the safety and effectiveness of using an unmanipulated G-CSF mobilized peripheral stem cell allograft from a haploidentical donor and post-transplant cyclophosphamide for patients with SAA, or SAA evolving to MDS, or PNH that has proven to be refractory to conventional immunosuppressive therapy (IST) in patients who lack an HLA-matched donor (sibling/ or matched unrelated donor.
Study: NCT02960490
Drug: E6011
Normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE6011
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous administration
Study: NCT02960490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous administration
Study: NCT00549679
Drug: GSK256066
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDE4 inhibitor
Study: NCT00549679
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03900754
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04569084
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02248883
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02248883
Drug: RTV
Normalized name: Accu-Chek SmartView Test Strips
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03932643
Drug: ONC-201
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONC-201 Capsules, 125 mg~Oral ONC-201 at various dose levels will be given at weekly intervals for up to 13 cycles (52 weeks); 4-week therapy will be considered 1 cycle.
Study: NCT01333397
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.M. on day 1 (single treatment cycle)
Study: NCT00428116
Drug: HAART
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination first line antiretrovirals as previously described.
Study: NCT00074828
Drug: LY517717
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01349777
Drug: Pregrel®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregrel® 75mg daily for 12 months
Study: NCT01349777
Drug: Plavix®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plavix® 75mg daily for 12 months
Study: NCT00206323
Drug: placebo/sugar pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03477903
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride for injection
Study: NCT00418002
Drug: AQW051
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02686138
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01953978
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet Ibuprofen 400 mg orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.
Study: NCT01406444
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections 30 mcg/kg BID, Placebo tablet PO once weekly
Study: NCT01180426
Drug: CHR-2797
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120mg once daily oral for 48 weeks
Study: NCT00673049
Drug: CP 751,871 (Figitumumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP 751,871 (20 mg/kg) will be administered as an IV infusion on study Days 1 and 2 in Cycle 1, and every three weeks (from Day 1) (Cycle) thereafter.
Study: NCT00376038
Drug: GSK189075 oral tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03616717
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week.
Study: NCT00967655
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03510598
Drug: Kybella 20 MG in 2 ML Injection
Normalized name: Kybella 20 MG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable drug called KYBELLA® (deoxycholic acid)
Study: NCT05300828
Drug: Genexl PM
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Every three weeks, after intravenous infusion of 260 mg/m2 for 3 hours, followed by carboplatin AUC 5 for 3 hours.
Study: NCT00201409
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by slow intravenous infusion once daily for 14 days.
Study: NCT00506792
Drug: QAU145
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00506792
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04229927
Drug: BPDO-1603
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm1 : 1 tablet of the test drug, and 1 tablet of placebo reference drug~Arm2 : 1 tablet of the reference drug, and 1 tablet of placebo test drug
Study: NCT02045589
Drug: Abraxane®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg/m2 intravenous administration
Study: NCT01855828
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered at 500mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
Study: NCT01866098
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01178710
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg per day, start at 5 days before surgery and continue for one year. For some congenital heart diseases which other drugs such as digoxin, antistone, furosemide were prescribed less than half year, simvastatin will be prescribed less than half year.
Study: NCT01374269
Drug: NSAID (Nonsteroidal anti-inflammatory drugs)
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: The second group was treated for 10 days with NSAIDs (naproxen 500 mg/d or celecoxib 200 mg/d) according to the indications and contraindications. The patients kept a journal stating whether they had taken the drug and any adverse reactions. If the pain intensity of any participant increased, acetaminophen (1.5 - 2.0 g/d) was proposed as a rescue procedure.
Study: NCT00497913
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02813265
Drug: KPI-121 0.25% Ophthalmic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02813265
Drug: Vehicle of KPI-121 0.25% Ophthalmic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00478244
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day -5 through Day -2: 50 mg/kg IV over 120 min.
Study: NCT00948324
Drug: CSII,ALA,MET,RSG
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSII along.ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD. RSG:CSII combined with three months rosiglitazoneor 4mg QD. MET:CSII combined with metformin 500mg BID-TID.
Study: NCT03669185
Drug: Pentalong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentalong, 2 x daily 1 tablet, intake max. 133 days
Study: NCT03669185
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos, 2 x daily 1 tablet, intake max. 133 days
Study: NCT03456388
Drug: placebo enteric-coated tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: There will be 7 ascending cohorts. The first cohort will be administered 2.5 mg once. The second cohort will be administered 7.5 mg. The third cohort will be administered 15 mg once. The forth cohort will be administered 30 mg once. The fifth cohort will be administered 45 mg once. The sixth cohort will be administered 65 mg once.The seventh cohort will be administered 100 mg once. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested.
Study: NCT04214626
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction Chemotherapy: 750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
Study: NCT04214626
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction Chemotherapy: 1g/m2, Intravenous administration on day 3 of each 3-week cycle from 2 to 5 cycles for patients with high recurrence risk of the central nervous system.
Study: NCT00663026
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous injection once per week for 6 months
Study: NCT01056289
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DVS SR Placebo Abrupt Discontinuation Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
Study: NCT02487303
Drug: Acetaminophen Intravenous
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV 1 gram f3 doses over 24 hours
Study: NCT00358410
Drug: GW679769 oral tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x GW679769 60mg tablets
Study: NCT00358410
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablets to match experimental intervention
Study: NCT01775189
Drug: ALO-02 weight-matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: crushed sugar spheres (powder) x 1 dose
Study: NCT01775189
Drug: crushed ALO-02 30 mg/3.6 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: crushed ALO-02 30 mg/3.6 mg capsule x 1 dose
Study: NCT02974712
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03988686
Drug: Standard of care for metastatic prostate cancer
Normalized name: PROSTATE CONCENTRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: androgen deprivation therapy with or without other systemic therapies based on current guidelines for metastatic prostate cancer
Study: NCT01755767
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets
Study: NCT04623086
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9g/L sodium chloride (normal saline) subcutaneous injection manufactured to mimic insulin glargine injection
Study: NCT01273896
Drug: STA-9090
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive 200 mg/m2 of STA-9090 once weekly by a 1-hour IV infusion for three consecutive weeks followed by a 1 week dose-free interval. Subjects tolerating therapy may continue on study until disease progression.
Study: NCT04380090
Drug: Propylene Glycol
Normalized name: Propylene Glycol
DrugBank: Propylene glycol (DB01839)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the propylene glycol arm will receive one standard dose of the drug on postoperative day one prior to discharge with the aim of decreasing rates of postoperative constipation for patients following single total knee replacement surgery
Study: NCT02548390
Drug: RXDX-107
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in this study will receive RXDX-107 intravenously at dose levels specified for their respective dose cohorts. Dosing will begin at 25 mg/m2 on Day 1 and Day 2 of a 28-day cycle and will escalate until the maximum tolerated dose (MTD) or (RP2D) is determined. An additional schedule of administration of RXDX-107 on Day 1 of a 28 day cycle may be assessed. Cycles will be repeated in four-week (28 day) intervals for up to 6 cycles or until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.
Study: NCT00425373
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tablet and 2 capsule placebos taken once daily
Study: NCT02597127
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (sterile, normal, 0.9%) solution given as SC injections
Study: NCT01008462
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03120780
Drug: Fentanyl 20 mcg
Normalized name: fentaNYL 20 mcg/mL-0.9% injectable solution
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mcg fentanyl in 10 mL 0.125% bupivacaine
Study: NCT01365312
Drug: Ethanol lock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placement of 0.5 cc 70% ethanol, every 72 hours, for 15 minutes, into PICC lines randomized to ethanol intervention
Study: NCT01365312
Drug: Heparinized saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 cc heparinized saline to be placed once every 72 hours for 15 minutes, in PICC lines randomized to placebo
Study: NCT03997279
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg 2x1, for 14 days, followed by 1x1 for 14 days, Amoxicillin 1000 mg 2x1, for 14 days, Clarithromycin 500 mg 2x1, for 14 days, Metronidazole 500 mg 2x1, for 14 days, Saccharomyces boulardi 500 mg 1x1, for 3 week
Study: NCT03997279
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg 2x1, for 14 days, followed by 1x1 for 14 days, Amoxicillin 1000 mg 2x1, for 14 days, Clarithromycin 500 mg 2x1, for 14 days, Metronidazole 500 mg 2x1, for 14 days, Placebo 1x1, for 3 week
Study: NCT03120780
Drug: Fentanyl 100 mcg
Normalized name: fentaNYL 100 mcg oral lozenge
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mcg fentanyl in 10 mL 0.125% bupivacaine
Study: NCT03526159
Drug: Gentamicin Sulfate
Normalized name: Gentamicin Sulfate
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gentamicin (formulated as gentamicin sulfate) is a well-known, well-characterized antibiotic that has been used for four decades as a treatment against gram negative bacteria. It, like other aminoglycoside antibiotics, has the well documented added potential to facilitate readthrough of premature termination codons in eukaryotic cells and organisms.
Study: NCT00645632
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00645632
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01968187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each spray pump actuation delivered a 50 μL volume of sterile sodium chloride solution 0.9%; each dose consisted of 3 spray pump actuations in each nostril.~Parents were instructed to administer 3 intranasal spray actuations in each nostril 3 times daily before meals for 14 days.
Study: NCT00819637
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 will receive nebulized arformoterol 15 ug first dose and then placebo every 20 minutes for 2 doses.
Study: NCT01316315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same as active
Study: NCT00002737
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01680107
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000620
Drug: Anti-hyperglycemic Agents
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals (intensive control \<6%; standard control 7.0-7.9%).
Study: NCT00000620
Drug: Anti-hypertensive Agents
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple anti-hypertensive agents as needed to reach Blood Pressure Trial arm-specific goals (intensive control \<120 mm Hg; standard control \<140 mm Hg).
Study: NCT00000620
Drug: Blinded fenofibrate or placebo plus simvastatin
Normalized name: fenofibrate / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR \<50 mL/min/1.73m2 or matching placebo in combination with open label simvastatin 20 - 40 mg/day.
Study: NCT03238612
Drug: FFA, clarithromycin, oseltamivir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-day course of triple combination of clarithromycin 500mg, flufenamic acid 200mg and oseltamivir 75mg twice daily followed by oseltamivir 75mg twice daily for 3 days
Study: NCT02876757
Drug: 5ARI
Normalized name: 5-alpha reductase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to finasteride/dutasteride
Study: NCT01090518
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 30mg 20 minutes prior to each PE session including imaginal exposure (8 total)
Study: NCT01006018
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin placebo 100 mg tablet daily + Pioglitazone placebo 15 mg capsule daily
Study: NCT03983915
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil was used to prevent cough induced by bronchoscopy.
Study: NCT03106987
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo~300mg placebo tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria.
Study: NCT01739699
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01739699
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00134004
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00890604
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: It is not the intent of the study to evaluate this drug but may be provided in conjunction with the Stepwise normothermia protocol.
Study: NCT00925639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch pill
Study: NCT00014352
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02871492
Drug: Zovirax® cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01114607
Drug: GSK1605786 ChemoCentryx: formulation A
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChemoCentryx formulation A will be an opaque Swedish orange body, blue coloured capsule with size zero, administered 30 minutes after standard breakfast.
Study: NCT01114607
Drug: GSK1605786 GSK: formulation B
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1605786 formulation B will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.
Study: NCT01114607
Drug: GSK1605786 GSK direct-fill: formulation C
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1605786 formulation C will be an opaque Swedish orange body capsule with size 1, administered 30 minutes after standard breakfast.
Study: NCT01114607
Drug: GSK1605786 GSK modified-process: formulation D
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1605786 formulation D will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.
Study: NCT01114607
Drug: GSK1605786 GSK tablet: formulation E
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1605786 formulation D will be a pink coloured film coated tablet, administered 30 minutes after standard breakfast.
Study: NCT01535092
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline, daily infused for 14-21 days pre-OLT and for 7 days post-OLT
Study: NCT02004015
Drug: injection of placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg milligram(s)/kilogram
Study: NCT02004015
Drug: injection of NMBA
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02558439
Drug: CNTX-4975
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03389815
Drug: WX-0593 Tablets
Normalized name: WX-554
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets, dosage ranged from 30 mg to 300 mg, quaque die（QD）
Study: NCT02285088
Drug: GBT440
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBT440 will be administered as oral capsules
Study: NCT02285088
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered as oral capsules